Prescribing information



Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

In this webinar, hear consultant dermatologists Dr Laura Savage and Dr Amy Foulkes as well as NIHR Clinician Scientist Professor Laura Coates share their approach to early management of skin and joint manifestations in patients with PsO. They discuss key predictors and identification of progression to PsA and GRAPPA treatment recommendations. Efficacy and safety data and head-to-head superiority versus ustekinumab for Cosentyx are also presented. Lastly, our specialists consider how to assess treatment success.

Click here for Cosentyx® (secukinumab) prescribing information


Want to be notified of upcoming webinars?

Click the button below


BAD, British Association of Dermatologists; BADBIR, British Association of Dermatologists Biologics and Immunomodulators Register; CRP, c-reactive protein; DMARD, disease-modifying anti-rheumatic drug; GP, general practitioner; MRI, magnetic resonance imaging; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis.

Rate this content: 
No votes yet
UK | December 2021 | 162970

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]